Navigation Links
Notre Dame chemists discover new class of antibiotics

A team of University of Notre Dame researchers led by Mayland Chang and Shahriar Mobashery have discovered a new class of antibiotics to fight bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and other drug-resistant bacteria that threaten public health. Their research is published in the Journal of the American Chemical Society in an article titled "Discovery of a New Class of Non-beta-lactam Inhibitors of Penicillin-Binding Proteins with Gram-Positive Antibacterial Activity."

The new class, called oxadiazoles, was discovered in silico (by computer) screening and has shown promise in the treatment of MRSA in mouse models of infection. Researchers who screened 1.2 million compounds found that the oxadiazole inhibits a penicillin-binding protein, PBP2a, and the biosynthesis of the cell wall that enables MRSA to resist other drugs. The oxadiazoles are also effective when taken orally. This is an important feature as there is only one marketed antibiotic for MRSA that can be taken orally.

MRSA has become a global public-health problem since the 1960s because of its resistance to antibiotics. In the United States alone, 278,000 people are hospitalized and 19,000 die each year from infections caused by MRSA. Only three drugs currently are effective treatments, and resistance to each of those drugs already exists.

The researchers have been seeking a solution to MRSA for years. "Professor Mobashery has been working on the mechanisms of resistance in MRSA for a very long time," Chang said. "As we understand what the mechanisms are, we can devise strategies to develop compounds against MRSA."

"Mayland Chang and Shahriar Mobashery's discovery of a class of compounds that combat drug resistant bacteria such as MRSA could save thousands of lives around the world. We are grateful for their leadership and persistence in fighting drug resistance," said Greg Crawford, dean of the College of Science at the University of Notre Dame.

Contact: Mayland Chang
University of Notre Dame

Related biology news :

1. Notre Dame paper sheds light on genetic and physiological basis for metabolic diseases
2. Notre Dame researchers develop system that uses a big data approach to personalized healthcare
3. Notre Dame study finds Asian carp DNA not widespread in the Great Lakes
4. Notre Dame researcher is studying role small dams play in pollution control
5. Notre Dame researchers are using new technologies to combat invasive species
6. Notre Dame research may have important implications for combating diabetes
7. Cargill expands support of Notre Dame Haiti Program
8. Notre Dame research reveals migrating Great Lakes salmon carry contaminants upstream
9. Notre Dame research could improve sustainability and cost effectiveness of wastewater treatment
10. Notre Dame research could provide new insights into tuberculosis and other diseases
11. Notre Dame researcher is shedding light on how jaws evolve
Post Your Comments:
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
(Date:10/29/2015)... Connecticut , October 29, 2015 ... a biometric authentication company focused on the growing ... smart wallet announces that StackCommerce, a leading marketplace ... be featuring the Wocket® smart wallet on StackSocial ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:10/27/2015)... Germany , October 27, 2015 ... SMI,s Automated Semantic Gaze Mapping technology (ASGM) automatically maps ... SMI,s Eye Tracking Glasses , so that they ... BeGaze. --> Munich, Germany , ... (ASGM) automatically maps data from mobile eye tracking videos ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... Nov. 24, 2015 HemoShear Therapeutics, LLC, ... drugs for metabolic disorders, announced today the appointment ... Board of Directors (BOD). Mr. Watkins is the ... Genome Sciences (HGS), and also served as the ... Jim Powers , Chairman and CEO of HemoShear ...
(Date:11/24/2015)... MUNICH and NEW YORK , ... irst investment by Bristol-Myers Squibb in a ... Bristol-Myers Squibb Company in which the companies ... products in immuno-oncology and other areas of unmet medical need. ... Squibb in LSP 5, the latest LSP fund. This is ...
(Date:11/24/2015)... Nov. 24, 2015 According to two new studies, ... This is something that many doctors, scientists, and public health ... remains: with fewer PSA tests being done, will there be ... Dr. David Samadi, "Despite the efforts made in ... the second leading cancer cause of death in men, killing ...
(Date:11/23/2015)... --  Ceres, Inc . (Nasdaq: CERE ), an ... fiscal year ended August 31, 2015 and provided an ... --> During fiscal year 2015, Ceres refocused ... a better balance of yield, energy and nutrition. Among ... leading crop input providers and made significant progress in ...
Breaking Biology Technology: